Sino Biopharmaceutical’s TQ-B3101 Accepted by NMPA for ROS1+ NSCLC Treatment
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that the National Medical Products Administration (NMPA)...
Ascletis Pharma Presents ASC22 Phase IIb Results for Chronic Hepatitis B at ILC 2022
China-based Ascletis Pharma Inc. (HKG: 1672) presented the latest results of a Phase IIb clinical...
Cosunter Pharma’s HBV Surface Antigen Inhibitor GST-HG121 Approved for Phase I Trial
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced receiving approval from the ethics...
Sanyou Biopharmaceuticals and Dragon Sail Form Strategic Partnership for Global Biopharma Services
China-based Sanyou Biopharmaceuticals Co., Ltd has entered into a long-term strategic partnership with compatriot firm...
NMPA Approves Senscure’s Cryoablation Catheter and Kangduo’s Laparoscopic Surgery System
The National Medical Products Administration (NMPA) has approved two innovative medical devices in China: Ningbo...
Westlake Therapeutics Secures RMB 100 Million in Series A+ Funding for Red Cell Therapy Pipeline
Hangzhou-based cell therapy firm Westlake Therapeutics, founded in 2019, has successfully raised over RMB 100...
PhenoVision Bio Secures Angel Funding for Spatial Multi-Omics Technology Platform
Beijing-based PhenoVision Biotech, a one-stop spatial multi-omics solution provider, has reportedly secured “tens of millions”...
GSK Launches Nucala in China for Eosinophilic Granulomatosis with Polyangiitis
UK pharmaceutical giant GlaxoSmithKline (GSK, LON: GSK, NYSE: GSK) has announced the official market launch...
Genor Biopharma and Abogen Biosciences Collaborate on Cancer mRNA Therapies
China’s Genor Biopharma Co., Ltd (HKG: 6998) has entered into a co-development agreement with compatriot...
Kexing Pharmaceutical’s Oral COVID-19 Drug SHEN26 Accepted for Clinical Trial Review
China-based Kexing Pharmaceutical (SHA: 688136) announced that a clinical trial application for SHEN26, an oral...
Sunshine Guojian Pharmaceutical Signs Licensing Deal for Cipterbin ADC Development
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has...
Takeda Pharmaceutical’s Teduglutide Filed for Marketing Approval in China
The Center for Drug Evaluation (CDE) website in China indicates that Japan-based Takeda Pharmaceutical Co.,...
Guangzhou Baiyunshan Halts Spinning-off of Guangzhou Pharmaceutical Amid HK Capital Shifts
China-based Guangzhou Baiyunshan Pharmaceutical Co., Ltd (SHA: 600332) has announced the suspension of the spinning-off...
Frontier Biotech’s Albuvirtide Shows Promising HIV Treatment Results in Phase III Trial
China-based Frontier Biotechnologies Inc. (SHA: 688221) has released Phase III trial data for albuvirtide, China’s...
Organon’s China Head Shi Wang Departs to Lead Sanofi Greater China
Women’s health specialist Organon (NYSE: OGN) announced the departure of its former China unit head...
Antengene Receives Australian TGA Approval for ATG-018 Clinical Trial
China-based biopharma Antengene Corporation (HKG: 6996) has announced receiving approval from the Therapeutic Goods Administration...
Helixon Secures RMB 500 Million in Series A Round to Advance AI-Driven Drug Development
Beijing-based Helixon, an artificial intelligence (AI)-empowered pharmaceutical company, has reportedly secured RMB 500 million (USD...
Jumbo Drug Bank’s JDB153 Enters Phase I Trial for Advanced Solid Tumors
Data from Fineline Cube indicates that JDB153, a potential first-in-class (FIC) small-molecule inhibitor targeting Mnk...
RemeGen’s Telitacicept Begins Global Phase III Trial for Severe SLE
China-based pharmaceutical firm RemeGen (HKG: 9995) has announced the first patient dosing in a global...
Suzhou Teligene Ltd Plans IPO on Shanghai STAR Market for Cancer Drug Development
China-based Suzhou Teligene Ltd has announced plans for an initial public offering (IPO) of 63.52...